Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

BREAKING NEWS
Source: Thailand Medical News  Jun 08, 2019  4 years, 10 months, 1 week, 4 days, 11 hours, 48 minutes ago

New Trial Results Show that Shorter Duration Of Herceptin (Trastuzumab) Is Effective For Prevention Of Breasts Cancer Return

New Trial Results Show that Shorter Duration Of Herceptin (Trastuzumab) Is Effective For Prevention Of Breasts Cancer Return
Source: Thailand Medical News  Jun 08, 2019  4 years, 10 months, 1 week, 4 days, 11 hours, 48 minutes ago
PERSEPHONE , A new trial study by the University of Warwick and the University Of Cambridge has shown that shortening the duration of a therapy for breast cancer patients does not increase the risk of their cancer returning.


 

This trial addresses the issues of concerning reduction in the length of treatments and attendant toxicities and whether this can be achieved without any worsening of outcomes.
 
Clinical trial results show that women treated with 6 months of Herceptin(trastuzumab) for HER2 positive early breast cancer did as well in terms of their risk of breast cancer returning as those getting the currently conventional 12 months treatment. The shorter duration also significantly reduced treatment related side effects, including heart problems.
 
The PERSEPHONE trial, recruited over 4,088 women with HER2-positive early-stage breast cancer. It compared a six month course of Herceptin with the current standard of twelve months to see whether the shorter treatment was just as effective. This is the largest trial of its kind examining the impact of shortening the duration of Herceptin
 
The trial showed  that 89.4% of patients taking six months treatment were free of breast cancer after four years compared with 89.8% o